Validation of a novel homogeneous assay for of HDL3-C measurement

Clinica Chimica Acta

Volumn 425, Issue , 2013, Pages 37-41

  Ashmaig, M E ^a   Gupta, S ^a   McConnell, J P ^a   Warnick, G R ^a  

^a Health Diagnostic Laboratory Inc   (United States)

Author keywords

CVD; HDL C; HDL subclasses; HDL2 C; HDL3 C

Indexed keywords

BILIRUBIN; DEXTRAN SULFATE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN 3 CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ACCURACY; ANALYTICAL PARAMETERS; ARTICLE; AUTOANALYZER; BIOASSAY; BLOOD SAMPLING; CHEMICAL ANALYZER; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; HUMAN; INTERMETHOD COMPARISON; LIMIT OF BLANK; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LINEAR SYSTEM; PRECIPITATION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; VALIDATION STUDY;

CVD; HDL(2)-C; HDL(3)-C; HDL-C; HDL-SUBCLASSES;

BILIRUBIN; CALIBRATION; CHEMICAL PRECIPITATION; CHOLESTEROL, HDL; COLORIMETRY; DEXTRAN SULFATE; HEMOGLOBINS; HUMANS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TRIGLYCERIDES;

EID: 84881349648     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2013.07.007     Document Type: Article

References (32)

1. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
2. Rye K.A., Bursill C.A., Lambert G., Tabet F., Barter P.J. The metabolism and anti-atherogenic properties of HDL. J Lipid Res 2009, 50:S195-S200. [Suppl.].
3. Florentin M., Liberopoulos E.N., Wierzbicki A.S., Mikhailidis D.P. Multiple actions of high-density lipoprotein. Curr Opin Cardiol 2008, 23:370-378.
4. de Silva H.V., Stuart W.D., Duvic C.R., et al. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. J Biol Chem 1990, 265:13240-13247.
5. Duchateau P.N., Pullinger C.R., Orellana R.E., et al. Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L. J Biol Chem 1997, 272:25576-25582.
6. Christoffersen C., Nielsen L.B., Axler O., Andersson A., Johnsen A.H., Dahlbäck B. Isolation and characterization of human apolipoprotein M-containing lipoproteins. J Lipid Res 2006, 47:1833-1843.
7. Gordon T., Castelli W.P., Hjortland M.C., Kannel W.B., Dawber T.R. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977, 62:707-714.
8. Gordon D.J., Rifkind B.M. High density lipoprotein: the clinical implications of recent studies. N Engl J Med 1989, 321:1311-1316.
9. Assmann G., Schulte H.Y. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Am J Cardiol 1992, 70:733-737.
10. Chapman M.J., Assmann G., Fruchart J., Shepherd J., Sirtori C. Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid-a position paper developed by the European Consensus Panel on HDL-C. Curr Med Res Opin 2004, 20:1253-1268.
11. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 2000, 86:19L-22L.
12. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001, 285:2486-2497.
13. Badimon J.J., Badimon L., Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterolfed rabbit. J Clin Invest 1990, 85:1234-1241.
14. Rubin E.M., Krauss R.M., Spangler E.A., Verstuyft J.G., Clift S.M. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991, 353:265-267.
15. DeLalla O.F., Elliot H.A., Gofman J.W. Ultracentrifugal studies of high-density serum lipoproteins in clinically healthy adults. Am J Physiol 1954, 179:333-337.
16. Gofman J.W., Young W., Tandy R. Ischemic heart disease, atherosclerosis and longevity. Circulation 1966, 34:79-97.
17. Miller N.E. Associations of high density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987, 113:589-597.
18. Cm Fievet, Fruchart J.C. HDL heterogeneity and coronary heart disease. Diabetes Metab Rev 1991, 7:155-162.
19. Lamarche B., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Després J.P. Associations of HDL2 and HDL3 subclasses with ischemic heart disease in men. Prospectiveresults from the Québec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997, 17:1098-1105.
20. Bakogianni M.C., Kalofoutis C.A., Skenderi K.I., Kalofoutis A.T. Clinical evaluation of plasma high-density lipoprotein subclasses (HDL2, HDL3) in non-insulin-dependent diabetics with coronary artery disease. J Diabetes Complication 2001, 15(5):265-269.
21. Umaerus M., Rosengren B., Fagerberg B., Hurt-Camejo E., Camejo G. HDL2 interferes with LDL association with arterial proteoglycans: a possible athero-protective effect. Atherosclerosis 2012, 225(1):115-120.
22. Wilson H.M., Patel J.C., Er Skinner The distribution of high-density lipoprotein subfractions in coronary survivors. Biochem Soc Trans 1990, 18:1175-1176.
23. Cheung M.C., Brown B.G., Wolf A.C., Albers J.J. Altered particle size distribution of apolipoprotein A-I-containing lipoproteins in subjects with coronary artery disease. J Lipid Res 1991, 32:383-394.
24. Johansson J., Carlson L.A., Landou C., Hamsten A. High density lipoproteins and coronary atherosclerosis: a strong inverse relation with the largest particles is confined to normotriglyceridemic patients. Arterioscler Thromb 1991, 11:174-182.
25. Superko H.R. Lipid altering drugs LDL/HDL subclass distribution. Match the treatment to the disorder. ACC Curr J Rev 2000, 9(3):18-24.
26. Blanche P.J., Gong E.L., Forte T.M., Nichols A.V. Characterization of human high-density lipoproteins by gradient gel electrophoresis. Biochim Biophys Acta 1981, 665:408-419.
27. Gidez L.I., Miller G.J., Burstein M., Slagle S., Eder H.A. Separation and quantitation of subclasses of human plasma high-density lipoproteins by simple precipitation procedure. J Lipid Res 1982, 23:1206-1223.
28. Warnick G.R., Benderson J.M., Albers J.J. Quantitation of high-density-lipoproteins subclasses after separation by dextran sulfate and Mg2 precipitation. [Abstract]. Clin Chem 1982, 28:1574.
29. Nguyen T., Warnick G.R. Improved methods for separation of total HDL and subclasses. [Abstract]. Clin Chem 1989, 35:1086.
30. NCCLS Evaluation of the linearity of quantitative measurement procedures: a statistical approach; approved guideline. NCCLS document EP6-A 2003, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
31. NCCLS Protocol for determination of limits of detection and limits of quantitation; approved guideline. NCCLS document EP17-A 2004, NCCLS, 940 West Valley Road, Suite 1400, Wayne, Pennsylvania 19087-1898 USA.
32. Vasan R.S., Pencina M.J., Robins S.J., et al. Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community. Circulation 2009, 120:2414-2420.